Attached files
| file | filename |
|---|---|
| EX-10.8 - EX-10.8 - Radius Health, Inc. | a16-6577_1ex10d8.htm |
| EX-10.2 - EX-10.2 - Radius Health, Inc. | a16-6577_1ex10d2.htm |
| EX-10.9 - EX-10.9 - Radius Health, Inc. | a16-6577_1ex10d9.htm |
| EX-31.1 - EX-31.1 - Radius Health, Inc. | a16-6577_1ex31d1.htm |
| EX-10.4 - EX-10.4 - Radius Health, Inc. | a16-6577_1ex10d4.htm |
| EX-10.10 - EX-10.10 - Radius Health, Inc. | a16-6577_1ex10d10.htm |
| EX-10.3 - EX-10.3 - Radius Health, Inc. | a16-6577_1ex10d3.htm |
| EX-10.7 - EX-10.7 - Radius Health, Inc. | a16-6577_1ex10d7.htm |
| EX-10.12 - EX-10.12 - Radius Health, Inc. | a16-6577_1ex10d12.htm |
| EX-31.2 - EX-31.2 - Radius Health, Inc. | a16-6577_1ex31d2.htm |
| EX-10.13 - EX-10.13 - Radius Health, Inc. | a16-6577_1ex10d13.htm |
| 10-Q - 10-Q - Radius Health, Inc. | a16-6577_110q.htm |
| EX-10.5 - EX-10.5 - Radius Health, Inc. | a16-6577_1ex10d5.htm |
| EX-10.6 - EX-10.6 - Radius Health, Inc. | a16-6577_1ex10d6.htm |
| EX-10.11 - EX-10.11 - Radius Health, Inc. | a16-6577_1ex10d11.htm |
| EX-32.1 - EX-32.1 - Radius Health, Inc. | a16-6577_1ex32d1.htm |
Exhibit 10.1
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2
Statement of Work
To the Agreement between RADIUS HEALTH, INC. (“RADIUS”) and LONZA Sales AG dated 16 of October 2007
Supplemental analytical services
|
Number |
|
RDS-001-SC003 |
|
|
|
Product Code/Name |
|
RDS-001 Abaloparatide |
|
|
|
Description of the proposed change |
|
Supplemental services requested by Radius: 1) Concentration testing with FG2 on 10 samples from Bioagilytix 2) Reissue CoA of reference standard 8AK1R data with current TG2/FG2 and M-076 methods | ||
|
|
|
| ||
|
Price Agreed |
|
1. [*]€ 2. [*]€
Total: [*]€ |
|
|
|
Radius |
|
Name: Naveen Palwai |
|
Date: 02/03/2016 |
|
Radius |
|
Name: Wajiha Khan |
|
Date: 02/03/2016 |
|
Lonza Sales AG |
|
Name: Paul Tastenhoye |
|
Date: 29/01/2016 |
|
Lonza Sales AG |
|
Name: Frederique Mutterer |
|
Date: 29/01/2016 |
Additional notes: /
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2
Detailed description of the proposed change
Activity 1: Concentration testing with FG2 on 10 samples from Bioagilytix + issue of an official test report.
Activity 2: Reissue CoA of reference standard 8AK1R data with current TG2/FG2 and M-076 methods
Timescale
By February 5th 2016
Price and Terms of Payment
1. Price
· Activity 1: [*]€
· Activity 2: [*]€
· Total price: [*]€
2. Payment
100% upon completion
oooOOOooo
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.